scholarly journals Preliminary Safety and Efficacy of Head and Neck Cooling Therapy After Concussion in Adolescent Athletes

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Joseph Congeni ◽  
Tamara Murray ◽  
Peyton Kline ◽  
Rachida Bouhenni ◽  
Danielle Morgan ◽  
...  
Keyword(s):  
Head And Neck ◽  
Adolescent Athletes ◽  
Safety And Efficacy ◽  
Neck Cooling

Sa1628 Safety and Efficacy of Overtubes for Preventing Cutaneous Metastasis During PEG Tube Placement in Patients With Head and Neck Cancer: a Single-Center Study

2014 ◽  
Vol 79 (5) ◽  
pp. AB280
Author(s):  
Crispin O. Musumba ◽  
Chiao-Yun (Julia) Hsu ◽  
Golo Ahlenstiel ◽  
Nicholas J. Tutticci ◽  
Kavinderjit S. Nanda ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Cutaneous Metastasis ◽  
Tube Placement ◽  
Single Center ◽  
Safety And Efficacy ◽  
Single Center Study ◽  
Peg Tube ◽  
Center Study

scholarly journals Safety and Efficacy of Salvage Neck Dissection Following Carbon-ion Radiotherapy with Chemotherapy for a Patient with Mucosal Malignant Melanoma of Head and Neck

Diagnostics ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. 82
Author(s):  
Hidenori Suzuki ◽  
Eiichi Sasaki ◽  
Risa Motai ◽  
Seiya Goto ◽  
Daisuke Nishikawa ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Head And Neck ◽  
Neck Dissection ◽  
Initial Treatment ◽  
Concurrent Chemotherapy ◽  
Carbon Ion Radiotherapy ◽  
Safety And Efficacy ◽  
Carbon Ion ◽  
Mucosal Malignant Melanoma ◽  
Salvage Neck Dissection

Mucosal malignant melanoma of the head and neck is a rare diagnosis. The safety and efficacy of salvage neck dissection following carbon–ion radiotherapy with concurrent chemotherapy are not well described, and carbon–ion radiation protocols have not been fully developed. A 77 year old woman with crT0N1M0 mucosal melanoma of the head and neck achieved a complete response following initial treatment with carbon–ion radiotherapy and concurrent chemotherapy. She was treated with salvage neck dissection for as a cervical lymph node metastasis 16 months after initial treatment. She experienced neither Clavien-Dindo Grade 3 or 4 postoperative complications nor subsequent recurrence of disease at 3 months following salvage neck dissection. Surgical specimens may be useful for future precision oncology based on the molecular biology of recurrence melanoma with poor prognosis.

scholarly journals Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma

2019 ◽  
Vol 30 ◽  
pp. v523-v524
Author(s):  
A. Italiano ◽  
P. Cassier ◽  
D. Roda ◽  
C.-C. Lin ◽  
K. Peltola ◽  
...  
Keyword(s):  
Head And Neck ◽  
Head And Neck Carcinoma ◽  
Safety And Efficacy ◽  
Neck Carcinoma

A phase IIb 4-arm open-label randomized study to assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 6041-6041 ◽  
Author(s):  
B. Krishnamurthyreddy ◽  
M. S. Vidyasagar ◽  
R. Koteshwar ◽  
A. Shenoy ◽  
L. Viswanath ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Head And Neck ◽  
Disease Free Survival ◽  
Free Survival ◽  
Safety And Efficacy ◽  
Risk Of Death ◽  
Concurrent Use ◽  
Group A ◽  
Group B

6041 Background: Patients (pt) with advanced inoperable squamous cell carcinoma of the head and neck (SCCHN) have poor radiotherapy alone (RT) outcome. EGFR is over-expressed in >90% SCCHN. h-R3mAb (BIOMAb/nimotuzumab/TheraCIM) is a humanized monoclonal antibody, a validated oncotherapeutic-targeting EGFR. Objective: To investigate the safety and efficacy of concurrent h-R3mAb in combination with chemoradiotherapy of SCCHN. Methods: September 2004–2005, pt 18–70 yrs, SCCHN stageIII-IVA, 113 screened, 92 enrolled and randomly asssigned to, Group A: radical radiotherapy (pt) and Group B: chemoradiotherapy (pt). Randomization within Group A: [RT]v/s[RT+h-R3mAb] and within Group B: [RT+CT]v/s[RT+CT+ h-R3mAb] (n = 23 in each arm). Protocol: Radiotherapy: TD: 66 Gy,2Gy/Fr,5Fr/w,6.5wks. Radiation sensitizer (chemotherapy): CDDP-50mg/wk x 6wks. Study Drug (h-R3mAb): 200 mg/wk I.V.60min x 6weeks. Results: Evaluable (n = 76) in Group A-36 and Group B-40. F/u Analysis at 30 months after end of RT. Survival rate ITT: Group B: CT+RT+hR3- 69.5% v/s CT+RT-21.7% (p - 0.0011), Group A: RT alone - 21.7% v/s RT+ hR3–39.1% (ns). Progression-free survival: RT alone - 3(13.04 %) v/s RT+hR3mAb-8 (34.78 %), RT+CT-5 (21.74 %) v/s RT+CT+hR3mAb-13 (56.52%). Median overall survival (OS): CT+RT+hR3 - NR* v/s CT+RT- 21.96 months (hazard ratio [HR]-0.337, p - 0.0018) and RT alone - 25.02 v/s RT+hR3 - NR*(HR-0.678, p - 0.39). Disease-free survival: CT+RT+hR3- NR*v/sCT+RT-21.30 mths (HR-0.344, p - 0.0052) and RT alone-25.02 v/s RT+hR3- NA* (HR-0.599, p - 0.32). (NR*- median OS is yet to be reached). Safety: few grade - 1/2AE, no HAMA observed. OS per protocol - adding h-R3mAb to chemoradiation resulted in a reduction in risk of death (rrd) by 85% (HR 0.15, p - 0.0006) and to RT a 36 % rrd (HR0.64, p - 0.33). Conclusions: Concurrent use of h-R3mAb with RT or RT+CT is safe and efficacious. It enhances radiation and chemotherapy responses. Concurrent use of h-R3mAb with chemoradiotherapy enhances long-term loco-regional control and survival. Adding biological agents to physically targeted modality improves long-term therapeutic outcome of SCCHN. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document